EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity

Sebastian Jäger iD, Birgit Piater iD, Stephan Dickgiesser iD, Jason Tonillo, Stefan Hecht, Jan Anderl, Francesca Minelli, Elisa Bertotti, Nicolas Rasche, Heikki Joensuu, Mark Barok, Christian Schröter iD

Bioconjugate Chemistry · 2026

DOI: 10.1021/acs.bioconjchem.6c00324 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Sebastian Jäger und 11 weiteren Autor:innen. Beteiligte Einrichtung: ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, 64293Darmstadt, Germany. Hauptthemen laut MEDLINE: Immunoconjugates, Immunoglobulin Fc Fragments, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Sigrid Jusélius Foundation, Merck Healthcare KGaA, Cancer Society of Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) based on Fc antigen-binding fragments (Fcabs) promise improved tumor penetration while retaining the FcRn-mediated long half-life. Building on prior spheroid studies, we directly compared a 50 kDa HER2-targeted Fcab-MMAE ADC with a matched 150 kDa control molecule (aDIG-Fcab-MMAE) consisting of the same HER2-targeting Fcab ADC equipped with additional non-targeting anti-digoxigenin (aDIG) Fab arms and trastuzumab Fab- and IgG-based ADCs (50 kDa T-Fab-MMAE and 150 kDa T-IgG-MMAE) using the same linker-payloads. Site-specific conjugation yielded high-purity DAR2 species with excellent serum stability. In vitro cytotoxicity assays revealed that Fcab-MMAE and aDIG-Fcab-MMAE exhibited lower potency compared to T-Fab-MMAE and T-IgG-MMAE, correlating with their approximately 10-fold lower binding affinity for HER2. A pharmacokinetic study in mice showed similar exposure for the Fcab-MMAE, its 150 kDa control, and a higher exposure for T-IgG-MMAE ADC, while the T-Fab-MMAE ADC cleared rapidly. In an NCI-N87 gastric cancer SCID mouse xenograft model, T-IgG-MMAE demonstrated superior efficacy, while Fcab-MMAE and aDIG-Fcab-MMAE showed similar efficacy despite their size difference, with T-Fab-MMAE showing lower efficacy. These data indicate that at similar exposure, reduced scaffold size alone may not improve in vivo efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesImmunoglobulin Fc FragmentsAntineoplastic AgentsHumansAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesTrastuzumabFemaleMiceMice, SCID

Stichwörter der Autor:innen

FcabHER2MMAEantibody−drug conjugatetumor penetrationxenograft tumor

Substanzen

ImmunoconjugatesErb-b2 Receptor Tyrosine KinasesImmunoglobulin Fc FragmentsTrastuzumabAntineoplastic Agents

Autor:innen und Institutionen

  • ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, 64293Darmstadt, Germany.
  • Innovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche 'A. Marxer,' an Affiliate of…
  • Early Protein Supply & Characterization, Merck Healthcare KGaA, 64293Darmstadt, Germany.
  • Laboratory of Molecular Oncology, Biomedicum, University of Helsinki, 00290Helsinki, Finland.
  • Helsinki University Hospital and University of Helsinki, 00290Helsinki, Finland.
  • Department of Oncology, Helsinki University Hospital and University of Helsinki, 00290Helsinki, Finland.

ORCID-Profile: Sebastian Jäger, Birgit Piater, Stephan Dickgiesser, Christian Schröter

Förderung

  • Sigrid Jusélius Foundation
  • Merck Healthcare KGaA
  • Cancer Society of Finland
  • Sigrid Jus?lius Foundation

Zitieren

APA

Jäger, S., Piater, B., Dickgiesser, S., Tonillo, J., Hecht, S., Anderl, J., Minelli, F., Bertotti, E., Rasche, N., Joensuu, H., Barok, M., & Schröter, C. (2026). Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.6c00324

Vancouver

Jäger S, Piater B, Dickgiesser S, Tonillo J, Hecht S, Anderl J, et al. Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.6c00324

BibTeX
@article{Jger2026,
  author = {Jäger, Sebastian and Piater, Birgit and Dickgiesser, Stephan and Tonillo, Jason and Hecht, Stefan and Anderl, Jan and Minelli, Francesca and Bertotti, Elisa and Rasche, Nicolas and Joensuu, Heikki and Barok, Mark and Schröter, Christian},
  title = {Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity},
  journal = {Bioconjugate Chemistry},
  year = {2026},
  doi = {10.1021/acs.bioconjchem.6c00324}
}
Kostenlos starten →